ARTICLE | Clinical News
Long-acting injectable iloperidone: Development discontinued
November 12, 2012 8:00 AM UTC
Titan disclosed in an SEC filing that Novartis decided to discontinue development of a long-acting, injectable formulation of iloperidone. Novartis will continue to commercialize Fanapt, an oral vers...